Year: 2024
Type: article
Abstract: Pulmonary arterial hypertension (PAH) is a rare, progressive, life-threatening disease that leads to the right ventricular heart failure and premature death. Available specific therapies act primarily as vasodilators and have a limited effect on the biological cause of the disease, that is, the uncontrolled proliferation of vascular endothelial and smooth muscle cells. Currently used drugs for the treatment of PAH, as well as potential drugs that are in various phases of clinical trials are reviewed in the article. The authors discuss also the issue of drug provision for patients with PAH.
Authors: V. Zakiev, T. Martynyuk, Y. Kotovskaya
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4403208707